HC Wainwright reissued their buy rating on shares of Translate Bio (NASDAQ:TBIO) in a research note published on Thursday morning, AnalystRatings.com reports. They currently have a $21.00 target price on the stock.
“Valuation and risks to achievement of target price. Our price target of $21/share is based on an equally-weighted composite of: (a) $16.9/share, as a 35x multiple of taxed and diluted $4.33 discounted back to FY19 at 18% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $25.6/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”,” the firm’s analyst wrote.
Other analysts also recently issued research reports about the stock. Roth Capital began coverage on shares of Translate Bio in a report on Tuesday, June 18th. They issued a buy rating and a $25.00 price objective for the company. Jefferies Financial Group started coverage on shares of Translate Bio in a report on Monday, July 22nd. They issued a buy rating and a $20.00 price objective for the company. Finally, Zacks Investment Research raised shares of Translate Bio from a sell rating to a hold rating in a report on Tuesday, July 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $22.75.
Translate Bio (NASDAQ:TBIO) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.09). The business had revenue of $1.17 million during the quarter, compared to the consensus estimate of $1.73 million. Translate Bio had a negative net margin of 2,696.98% and a negative return on equity of 84.22%. Equities analysts expect that Translate Bio will post -1.96 EPS for the current year.
Several institutional investors have recently modified their holdings of TBIO. BlackRock Inc. lifted its holdings in shares of Translate Bio by 130.2% during the 4th quarter. BlackRock Inc. now owns 982,405 shares of the company’s stock worth $7,367,000 after acquiring an additional 555,635 shares during the period. FMR LLC lifted its holdings in shares of Translate Bio by 6.8% during the 4th quarter. FMR LLC now owns 6,771,313 shares of the company’s stock worth $50,785,000 after acquiring an additional 433,952 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Translate Bio by 139.0% during the 4th quarter. Geode Capital Management LLC now owns 117,432 shares of the company’s stock worth $880,000 after acquiring an additional 68,300 shares during the period. Fosun International Ltd lifted its holdings in shares of Translate Bio by 56.1% during the 1st quarter. Fosun International Ltd now owns 115,488 shares of the company’s stock worth $1,138,000 after acquiring an additional 41,488 shares during the period. Finally, Norges Bank bought a new stake in shares of Translate Bio during the 4th quarter worth approximately $263,000. 57.90% of the stock is owned by institutional investors.
About Translate Bio
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Featured Story: What is a recession?
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.